 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shilpa Standalone September 2023 Net Sales at Rs 74.61 crore, up 8.56% Y-o-Y

Shilpa Consolidated September 2023 Net Sales at Rs 312.98 crore, up 19.05% Y-o-Y

The share touched a 52-week high of Rs 384.70 and a 52-week low of Rs 222.40 on 31 August, 2023 and 28 March, 2023, respectively.

Shilpa Medicare shares up 2% on acquiring US-based Pilnova Pharma

Shilpa Medicare announced that the 36th Annual General Meeting (AGM) of the company will be held on 29 September 2023.

Shilpa Medicare AGM scheduled

In an exchange filing, the pharma company said that Shilpa Pharma Lifesciences active pharmaceutical ingredient (API) manufacturing facility, Unit II, situated at Raichur in Karnataka state has undergone a GMP inspection by Pharmaceuticals and Medical Devices Agency (PMDA), Japan starting 29 August 2023.The inspection has concluded successfully on 1 September 2023 without any criticalmajor observation, it added.The facility is involved in manufacturing various oncology and non&#8208;oncology APIs.  The company stated that it remains committed to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities. Meanwhile, Shilpa Medicare informed that it has received marketing authorization from Medicines and Healthcare Products Regulatory Agency (MHRA), UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg.Betahistine is indicated for the treatment of vertigo, tinnitus, hearing loss and nausea associated with Menieres syndrome and is available as tablets and oral liquid dosage forms in various strengths across UK, Europe. The Orally dispersibledissolvable film formulation offers benefits with respect to patient compliance and ease of administration.The drug maker said that it is the first company to receive approval for the 24 mg strength as a Film formulation in UK. The companys approval is a hybrid product application, which is bioequivalent to the reference product, it added.This approval has come from the companys finished dosage form manufacturing facility, Shilpa Medicare, Unit VI, located at Dabaspet, Bengaluru, Karnataka. The facility is approved by MHRA UK and this is the first approval for a prescription Oral Film product in regulated market from this facility. The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (oral dispersibledissolving Films and Transdermal Patches).  Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated marketsThe companys consolidated net profit jumped 38.8% to Rs 1.18 crore as compared with Rs 0.85 crore in Q1 FY23. Net sales fell 0.4% year on year to Rs 260.17 crore in Q1 FY24.Shares of Shilpa Medicare gained 0.98% to Rs 374.60 on the BSE.

Shilpa Medicare Karnataka unit clears PMDA inspection 

The company received marketing authorization from Medicines and Healthcare Products Regulatory Agency, UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg

Shilpa Medicare up on UK nod to market vertigo drug, clearing Japanese inspection

 Shilpa Medicare announced that the Companyfs finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana state has undergone a GMP inspection by ANVISA, Brazil starting 21 August 2023. The inspection has concluded successfully on 24 August 2023 without any observations.  The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (sterile injections and non]sterile oral solids) for the treatment of various forms of cancer and adjuvant therapy.  This inspection is the third major regulatory inspection (after Russia and Canada), cleared by this Site in the past two years. This inspection and subsequent approval will allow the company for the commercial distribution of products in Brazil market and enable approval of new applications for Brazil market.  

Shilpa Medicare's Unit IV clears inspection by Brazilian Health Authority - ANVISA 

The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (sterile injections and non&#8208;sterile oral solids) for the treatment of various forms of cancer and adjuvant therapy.    The inspection was carried from 21 August 2023 to 24 August 2023, the inspection has concluded without any observations.This inspection is the third major regulatory inspection (after Russia and Canada), cleared by this Site in the past two years. This inspection and subsequent approval will allow the company for the commercial distribution of products in Brazil market and enable approval of new applications for Brazil market. The firm said that it remains committed to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities.   Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated marketsThe companys consolidated net profit jumped 38.8% to Rs 1.18 crore as compared with Rs 0.85 crore in Q1 FY23. Net sales fell 0.4% year on year to Rs 260.17 crore in Q1 FY24. The scrip declined 0.56% to Rs 363.55 on the BSE.

Shilpa Medicare's Telangana facility clears ANVISA, Brazil inspection 

Shilpa Consolidated June 2023 Net Sales at Rs 260.17 crore, down 0.38% Y-o-Y

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 10 August 2023.

Shilpa Medicare to declare Quarterly Result

Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical products and wind power generation. The company was founded on November 20, 1987 and is headquartered in Raichur, India.

Watchers	27
52-Wk Low	222.60
52-Wk High	397.00

Market Cap	31.06B
Volume (M)	181,994.00
52-Wk High	397.00
52-Wk Low	222.60

Current Price	363.40
Prev Close	369.35
Open	371.60
Dividend Yield	0.00%
50-Day Moving Average	353.72
Beta	0.01
Avg. Volume	410,754.62
PE Ratio	-270.07

52-Week High	397.00
52-Week Low	222.60
Market Capitalization	31.06B
EPS	-1.37
Price to Book	1.80
Revenue Per Employee	9.32M
Enterprise Value/EBITDA	22.19

SHILPAMED.NSE Shilpa Medicare Ltd.

About

Feed

News

Sentiment

Fundamentals